Skip to content

Adding an oral contraceptive did not show an overall sexual-function advantage in PCOS

Both groups received vitamin D. The contraceptive group had no significant overall advantage, while the placebo group reported greater sexual desire at follow-up.

By 100HP editorialAbstract-based explanation checked

Based on the published abstract. The full paper may contain additional methods, results and limitations.

The 30-second takeaway

Among women with PCOS and vitamin D deficiency, adding a low-dose oral contraceptive did not produce a statistically significant overall sexual-function advantage over vitamin D with placebo. Sexual desire favored the placebo group at follow-up. Because everyone received vitamin D, this comparison cannot establish that the supplement itself caused the reported improvements.

Keep in mind

The abstract's wording about when overall sexual-function scores improved is unclear. It provides no between-group effect sizes or confidence intervals, and there was no group without vitamin D to isolate the supplement's effect.

THE NUMBERS, WITH CONTEXT

What researchers found

P = 0.009 and P = 0.01

Sexual desire at 3 and 6 months, respectively

Desire was greater with placebo plus vitamin D than with contraceptive plus vitamin D. These P values do not describe the size of the difference.

Arch Gynecol Obstet, 2025 · Original source ↓

What the randomization tested

The randomized difference was the contraceptive pill versus a similar placebo. Vitamin D was shared by both groups, so changes within either group do not isolate the effects of supplementation.

Overall and specific outcomes

The overall sexual-function conclusion and the sexual-desire result concern different outcomes. A nonsignificant overall difference does not establish equivalence, while a significant desire difference does not reveal how noticeable it was.

CHECK THE ORIGINAL

The original publication

The effect of hormonal contraceptives combined with vitamin D3 supplements on sexual dysfunction in women with polycystic ovary syndrome: a randomized double-blind placebo-controlled trial.

Jahanian Sadatmahalleh S, Razavinia F, Lotfi R et al.
Arch Gynecol Obstet · 2025

PubMed ID
40913650
Record checked

AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.